In modern-day medicine, nanotechnology and nanoparticles are some of the indispensable
tools in disease monitoring and therapy. The term “nanomaterials” describes materials with …

Hydrogen-bond donors are seen to cause more problems for drug designers than hydrogen-
bond acceptors. Most of the polarity in drug-like compounds comes from hydrogen-bond …

Microphysiological systems (MPSs) are in vitro models that capture facets of in vivo organ
function through use of specialized culture microenvironments, including 3D matrices and …

Brain delivery is one of the major challenges in drug development because of the high
number of patients suffering from neural diseases and the low efficiency of the treatments …

The blood–brain barrier (BBB) is a critical biological structure that prevents damage to the
brain and maintains its bathing microenvironment. However, this barrier is also the obstacle …

Nearly one in six people worldwide suffer from disorders of the central nervous system
(CNS). There is an urgent need for effective strategies to improve the success rates in CNS …

Ischemic stroke, a major cause of mortality in the United States, often contributes to
disruption of the blood-brain barrier (BBB). The BBB along with its supportive cells …

Abstract Parkinson's disease (PD), a neurodegenerative disease that shows a high
incidence in older individuals, is becoming increasingly prevalent. Unfortunately, there is no …

Glucose transporters (GLUTs) at the blood-brain barrier maintain the continuous high
glucose and energy demands of the brain. They also act as therapeutic targets and provide …

In recent decades, in silico absorption, distribution, metabolism, excretion (ADME), and
toxicity (T) modelling as a tool for rational drug design has received considerable attention …